Knight Therapeutics Stock Today
| KHTRF Stock | USD 3.85 0.04 1.05% |
Performance0 of 100
| Odds Of DistressLess than 21
|
Knight Therapeutics is trading at 3.85 as of the 4th of December 2024. This is a 1.05 percent increase since the beginning of the trading day. The stock's lowest day price was 3.85. Knight Therapeutics has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Knight Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of November 2024 and ending today, the 4th of December 2024. Click here to learn more.
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. Knight Therapeutics Inc. The company has 113.96 M outstanding shares. More on Knight Therapeutics
Moving together with Knight Pink Sheet
| 0.63 | BKRKF | PT Bank Rakyat | PairCorr |
| 0.9 | BKRKY | Bank Rakyat | PairCorr |
| 0.9 | TLK | Telkom Indonesia Tbk | PairCorr |
| 0.68 | PTAIY | Astra International Tbk | PairCorr |
Moving against Knight Pink Sheet
| 0.79 | CSCO | Cisco Systems Aggressive Push | PairCorr |
| 0.79 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.72 | WMT | Walmart Aggressive Push | PairCorr |
| 0.69 | AXP | American Express Sell-off Trend | PairCorr |
| 0.66 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.63 | T | ATT Inc Aggressive Push | PairCorr |
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Knight Pink Sheet Highlights
| Business Concentration | Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Knight Therapeutics [KHTRF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Small-Cap' category with a current market capitalization of 444.73 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Knight Therapeutics's market, we take the total number of its shares issued and multiply it by Knight Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Knight Therapeutics classifies itself under Biotechnology sector and is part of Health Care industry. The entity has 113.96 M outstanding shares.
Knight Therapeutics has accumulated about 147.08 M in cash with 44.62 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28.
Check Knight Therapeutics Probability Of Bankruptcy
Ownership AllocationKnight Therapeutics maintains a total of 113.96 Million outstanding shares. Knight Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Knight Ownership Details
Knight Therapeutics Risk Profiles
| Mean Deviation | 0.7321 | |||
| Standard Deviation | 1.57 | |||
| Variance | 2.47 | |||
| Risk Adjusted Performance | (0.04) |
Knight Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Knight Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Knight Therapeutics Corporate Management
| BA BA | Ex Chairman | Profile | |
| Arvind Utchanah | Chief Officer | Profile | |
| Leopoldo Bosano | VicePres Operations | Profile | |
| Susan Emblem | Global HR | Profile | |
| Jody Engel | Sr Devel | Profile | |
| Jeff Martens | Global Commercial | Profile | |
| Daniela Marino | Global Compliance | Profile |
Other Information on Investing in Knight Pink Sheet
Knight Therapeutics financial ratios help investors to determine whether Knight Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.